Summit Therapeutics Inc. (SMMT)
Summit Therapeutics Statistics
Share Statistics
Summit Therapeutics has 737.63M shares outstanding. The number of shares has increased by 5.05% in one year.
| Shares Outstanding | 737.63M |
| Shares Change (YoY) | 5.05% |
| Shares Change (QoQ) | 1.76% |
| Owned by Institutions (%) | 11.62% |
| Shares Floating | 114.92M |
| Failed to Deliver (FTD) Shares | 41.3K |
| FTD / Avg. Volume | 1.74% |
Short Selling Information
The latest short interest is 21.52M, so 2.92% of the outstanding shares have been sold short.
| Short Interest | 21.52M |
| Short % of Shares Out | 2.92% |
| Short % of Float | 18.78% |
| Short Ratio (days to cover) | 8.95 |
Valuation Ratios
The PE ratio is -57.95 and the forward PE ratio is -77.98. Summit Therapeutics's PEG ratio is 0.84.
| PE Ratio | -57.95 |
| Forward PE | -77.98 |
| PS Ratio | 0 |
| Forward PS | 5.9 |
| PB Ratio | 32.99 |
| P/FCF Ratio | -90.17 |
| PEG Ratio | 0.84 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Summit Therapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.15, with a Debt / Equity ratio of 0.02.
| Current Ratio | 10.15 |
| Quick Ratio | 10.15 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 1.82 |
| Cash Flow / Debt | -19.69 |
| Interest Coverage | -0.04 |
Financial Efficiency
Return on equity (ROE) is -0.57% and return on capital (ROIC) is 0.08%.
| Return on Equity (ROE) | -0.57% |
| Return on Assets (ROA) | -0.51% |
| Return on Capital (ROIC) | 0.08% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1,391,918.24 |
| Employee Count | 159 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 326.12% in the last 52 weeks. The beta is -1.04, so Summit Therapeutics's price volatility has been lower than the market average.
| Beta | -1.04 |
| 52-Week Price Change | 326.12% |
| 50-Day Moving Average | 19.89 |
| 200-Day Moving Average | 15.81 |
| Relative Strength Index (RSI) | 45.94 |
| Average Volume (20 Days) | 2.38M |
Income Statement
| Revenue | n/a |
| Gross Profit | -15.01M |
| Operating Income | 313K |
| Net Income | -221.31M |
| EBITDA | 313K |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.31 |
Balance Sheet
The company has 104.86M in cash and 7.22M in debt, giving a net cash position of 97.64M.
| Cash & Cash Equivalents | 104.86M |
| Total Debt | 7.22M |
| Net Cash | 97.64M |
| Retained Earnings | -1.21B |
| Total Assets | 435.56M |
| Working Capital | 382.02M |
Cash Flow
In the last 12 months, operating cash flow was -142.11M and capital expenditures -139K, giving a free cash flow of -142.25M.
| Operating Cash Flow | -142.11M |
| Capital Expenditures | -139K |
| Free Cash Flow | -142.25M |
| FCF Per Share | -0.2 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SMMT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1.62% |
| FCF Yield | -1.01% |
Analyst Forecast
The average price target for SMMT is $32, which is 67.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $32 |
| Price Target Difference | 67.6% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Scores
| Altman Z-Score | 169.5 |
| Piotroski F-Score | 5 |